A Magyar Tüdőgyógyász Társaság Magyar Bronchológus Egyesületének és Onkopulmonológiai Szekciójának konferenciája 2022. szeptember végén zajlott. A következőkben a rendezvény egyes előadásait összefoglalva mutatjuk be a nem kissejtes tüdőrák (non-small cell lung cancer, NSCLC) kezelését meghatározó legújabb klinikai vizsgálatokat, a befogadott új indikációkat a korai stádium neoadjuváns és adjuváns, illetve az...

 Idén áprilisban Visegrádon került megrendezésre a XI. Amgenius Akadémia, amelyet – ahogy ezt már megszokhattuk – ezúttal is színvonalas előadások, tudományos újdonságok és pezsgő szakmai viták jellemeztek....

ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV...

A randomized phase III trial indicates that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone. Nivolumab alone more than doubled the average time to disease progression, compared to ipilimumab (6.9 months vs. 2.9 months), and the benefit was even greater when ipilimumab and nivolumab were combined (11.5 months). The response rates were also substantially higher in patients...

CHICAGO – Findings presented today at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) provide long-sought, conclusive answers about the impact of less aggressive therapy on childhood cancer survival; the optimal timing of surgery for oral cancer; and the use of whole-brain radiation for patients with brain metastases. Another study provides a powerful new immunotherapy option for patients with melanoma. All four ...

A randomized phase III study resolves long-standing questions about the optimal timing of neck lymph node surgery for patients with early-stage oral cancer. It shows that a preventive approach, known as elective neck dissection (END), both improves survival and lowers recurrence rates compared to therapeutic neck dissection (TND) performed at the time of nodal occurrence....

An analysis of over 34,000 participants in the federally funded Childhood Cancer Survivor Study shows improvement in late mortality achieved over three decades. Among five-year survivors, all-cause mortality at 15 years of diagnosis dropped from 12.4% to 6%. This improvement is attributed in part to changes in care that reduced the risk of mortality related to late effects of pediatric cancer treatment, such as subsequent malignancies and cardiac...

A federally funded phase III trial provides additional information regarding a long-standing discussion about the impact of adjuvant whole brain radiation therapy (WBRT) on cognitive function. Patients with 1-3 small brain metastases who received radiosurgery followed by WBRT were more likely to experience cognitive decline than those who received radiosurgery alone. Furthermore, WBRT did not significantly extend patient survival, though it did ...

A phase II trial suggests that anti-CD38 antibody daratumumab is effective as a standalone therapy for heavily treated multiple myeloma. In a group of 106 patients whose disease worsened after at least three prior treatments, nearly one in three responded to daratumumab, and disease progression was delayed by 3.7 months, on average. The estimated one-year overall survival rate was 65%....

CHICAGO – Results from four pivotal clinical trials show that new targeted therapies could vastly improve treatment for people with chronic-lymphocytic leukemia (CLL), myelofibrosis, indolent non-Hodgkin lymphoma (NHL), and multiple myeloma. These important, late-breaking studies were presented today at the American Society of Clinical Oncology’s (ASCO) 51st Annual Meeting.

The four clinical trials reveal new therapies that extend cancer ...

Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL). Among patients for whom rituximab therapy no longer provided benefit, the average duration of remission was 29.2 months after receiving the new combination vs. 14 months after bendamustine alone. The trial was stopped early based on...

Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments. At 24 weeks of treatment, 19.1% of patients on the pacritinib arm experienced spleen shrinkage, compared to only 4.7% of patients on the BAT arm....

An interim analysis of a large phase III study suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients with chronic-lymphocytic leukemia (CLL) that worsened despite prior therapy....

CHICAGO – Results from five late-breaking studies released today at the American Society of Clinical Oncology’s (ASCO) 51st Annual Meeting provide important new treatment options for patients with common and rare cancers. They include new or refined therapies for melanoma, prostate and breast cancers, which are together diagnosed in more than 500,000 Americans annually. Another study reveals a long-awaited new treatment for patients with ...

Findings from a randomized phase III trial point to a promising new therapy for patients with advanced intermediate or high grade liposarcoma or leiomyosarcoma whose disease worsened after two or more lines of initial therapies. Patients treated with the chemotherapy drug eribulin had a two-month increase in median overall survival compared to those treated with the standard drug dacarbazine....

A randomized study finds that surgical removal of the lymph nodes surrounding a melanoma tumor after a positive lymph node biopsy (melanoma found in node) does not improve survival. The study will likely change practice and conclude a long-standing debate about the role of this approach, called complete lymph node dissection (CLND). More importantly, the new knowledge gained from this study will help spare thousands of patients with melanoma from...

A federally funded phase III study found that adding docetaxel chemotherapy to standard hormone and radiation therapy reduces the risk of death for men with high-risk, localized prostate cancer. At an average follow-up of 5.5 years, four-year overall survival rates were 89% in the standard therapy group vs. 93% in the docetaxel group....

The phase III registration study PALOMA-31 reports that adding the investigational targeted agent palbociclib to standard hormonal therapy (fulvestrant) more than doubled the duration of disease control, delaying disease progression by roughly five months in women with previously treated, hormone receptor-positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer. This trial was stopped early based on efficacy ...

A federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention. The study compared the standard five-year treatment of tamoxifen to five years of the aromatase inhibitor anastrazole in more than 3,000 DCIS survivors. The 10-year breast cancer-free survival rates were higher in the anastrazole group than in the tamoxifen group (93.5% vs. 89.2%)....